Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.38 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553691 | 0.83 | ADRB2 (0.52) | ADRB2ADRA2AMAPTOPRK1 | |
| SCHEMBL20553462 | 0.81 | ADRB2 (0.56) | MCHR1ADRB2ADRA2AHTR1ADRD2 | |
| SCHEMBL21751215 | 0.76 | DRD4 (0.45) | OPRK1 | |
| SCHEMBL21751233 | 0.75 | ADRB2 (0.56) | HTR7ADRB2ADRA2AHTR1AMAPT | |
| SCHEMBL20551616 | 0.75 | ADRB2 (0.63) | HTR7ADRB2ADRA2AHTR1AMAPT | |
| SCHEMBL31258553 | 0.72 | ADRA1A (0.40) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL21751230 | 0.72 | ADRA1A (0.40) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL21751225 | 0.72 | ADRB2 (0.50) | ADRB2ADRA2AMAPTOPRK1 | |
| SCHEMBL21751220 | 0.72 | ADRB2 (0.50) | HTR7ADRB2ADRA2AHTR1ADRD2 | |
| SCHEMBL24410084 | 0.65 | OPRK1 (0.42) | ADRB2ADRA2AMAPTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | DREXEL UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-12152036-B2 | Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2024-11-26 | — | — | US | disclosed |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | UNIV DREXEL (US) | 2022-05-12 | — | — | US | disclosed |
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | DREXEL UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| WO-2018204370-A1 | CX3CR1 SMALL MOLECULE ANTAGONISTS, AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | MCHR1 988/4885HTR7 568/4885ADRB2 517/4885 |
| US-20220144845-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | MCHR1 988/4885HTR7 568/4885ADRB2 517/4885 |
| US-20200062768-A1 | CX3CR1 Small Molecule Antagonists, and Methods Using Same | CX3CR1, CCR5, CXCR3 | MCHR1 704/4885HTR7 712/4885ADRB2 621/4885 |
| US-11267817-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCR5, CCL2 | MCHR1 826/4885HTR7 598/4885ADRB2 597/4885 |
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCL2, CCR2 | MCHR1 481/4885HTR7 464/4885ADRB2 250/4885 |
| US-12152036-B2 | Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCR5, CCL2 | MCHR1 1020/4885HTR7 583/4885ADRB2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.